ARDX
Ardelyx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.43B
P/E Ratio
—
EPS
$-0.24
Beta
0.58
52W High
$8.40
52W Low
$3.49
50-Day MA
$6.18
200-Day MA
$6.13
Dividend Yield
—
Profit Margin
-13.60%
Forward P/E
40.65
PEG Ratio
-0.08
About Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
Fundamentals
| Revenue (TTM) | $427.68M |
| Gross Profit (TTM) | $318.86M |
| EBITDA | $-34.05M |
| Operating Margin | -34.70% |
| Return on Equity | -39.50% |
| Return on Assets | -5.11% |
| Revenue/Share (TTM) | $1.76 |
| Book Value | $0.60 |
| Price-to-Book | 9.62 |
| Price-to-Sales (TTM) | 3.34 |
| EV/Revenue | 3.275 |
| EV/EBITDA | 130.88 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 27.50% |
| Shares Outstanding | $247.03M |
| Float | $219.85M |
| % Insiders | 3.19% |
| % Institutions | 70.66% |
Historical Volatility
HV 10-Day
42.49%
HV 20-Day
40.24%
HV 30-Day
48.30%
HV 60-Day
45.63%
HV Rank
31.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($16.33 target)
1
Strong Buy9
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026